Florin Despa

Florin Despa

Auto-generated profile, based on publicly available information

Florin Despa

Department of Pharmacology and Nutritional Sciences University of Kentucky Lexington Kentucky USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2014 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
SSSarah Srodulski
Sarah Srodulski
SSSavita Sharma
Savita Sharma
ABAdam B Bachstetter
Adam B Bachstetter
JBJennifer M Brelsfoard
Jennifer M Brelsfoard
CPConrado Pascual
Conrado Pascual
FDFlorin Despa
Florin Despa
We recently found that brain tissue from patients with type-2 diabetes (T2D) and cognitive impairment contains deposits of amylin, an amyloidogenic hormone synthesized and co-secreted with insulin by pancreatic β-cells. Amylin deposition is promoted by chronic hypersecretion of amylin (hyperamylinemia), which is common in humans with obesity or pre-diabetic insulin resistance. Human amylin oligomerizes quickly when oversecreted, which is toxic, induces inflammation in pancreatic islets and contributes to the development of T2D. Here, we tested the hypothesis that accumulation of oligomerized amylin affects brain function.

17 February 2012 in Circulation Research
Verified
Journal Article
Closed access
PDF file
SDSanda Despa
Sanda Despa
KMKenneth B. Margulies
Kenneth B. Margulies
LCLe Chen
Le Chen
AKAnne A. Knowlton
Anne A. Knowlton
PHPeter Havel
Peter Havel
FDFlorin Despa
Florin Despa
Rationale:: Hyperamylinemia is common in patients with obesity and insulin resistance, coincides with hyperinsulinemia, and results in amyloid deposition. Amylin amyloids are generally considered a pancreatic disorder in type 2 diabetes. However, elevated circulating levels of amylin may also lead to amylin accumulation and proteotoxicity in peripheral organs, including the heart. Objective:: To test whether amylin accumulates in the heart of obese and type 2 diabetic patients and to uncover the effects of amylin accumulation on cardiac morphology and function. Methods and Results:: We compared amylin deposition in failing and nonfailing hearts from lean, obese, and type 2 diabetic humans using immunohistochemistry and Western blots. We found significant accumulation of large amylin oligomers, fibrils, and plaques in failing hearts from obese and diabetic patients but not in normal hearts and failing hearts from lean, nondiabetic humans. Small amylin oligomers were even elevated in nonfailing hearts from overweight/obese patients, suggesting an early state of accumulation. Using a rat model of hyperamylinemia transgenic for human amylin, we observed that amylin oligomers attach to the sarcolemma, leading to myocyte Ca 2+ dysregulation, pathological myocyte remodeling, and diastolic dysfunction, starting from prediabetes. In contrast, prediabetic rats expressing the same level of wild-type rat amylin, a nonamyloidogenic isoform, exhibited normal heart structure and function. Conclusions:: Hyperamylinemia promotes amylin deposition in the heart, causing alterations of cardiac myocyte structure and function. We propose that detection and disruption of cardiac amylin buildup may be both a predictor of heart dysfunction and a novel therapeutic strategy in diabetic cardiomyopathy.

11 July 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
HLHan Ly
Han Ly
NVNirmal Verma
Nirmal Verma
FWFengen Wu
Fengen Wu
MLMiao Liu
Miao Liu
KSKathryn E. Saatman
Kathryn E. Saatman
FDFlorin Despa
Florin Despa

22 June 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
NVNirmal Verma
Nirmal Verma
HLHan Ly
Han Ly
MLMiao Liu
Miao Liu
JCJing Chen
Jing Chen
HZHaining Zhu
Haining Zhu
FDFlorin Despa
Florin Despa
Amylin is a hormone synthesized and co-secreted with insulin by pancreatic β-cells that crosses the blood-brain barrier and regulates satiety. Amylin from humans (but not rodents) has an increased propensity to aggregate into pancreatic islet amyloid

1 January 2020 in Kidney International
Verified
Journal Article
Closed access
NVNirmal Verma
Nirmal Verma
MLMiao Liu
Miao Liu
HLHan Ly
Han Ly
ALAnalia Loria
Analia Loria
KCKenneth S. Campbell
Kenneth S. Campbell
FDFlorin Despa
Florin Despa

15 August 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
SDSanda Despa
Sanda Despa
SSSavita Sharma
Savita Sharma
THTodd R. Harris
Todd R. Harris
HDHua Dong
Hua Dong
NLNing Li
Ning Li
FDFlorin Despa
Florin Despa
Background: Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and whether controlling hyperamylinemia protects the heart. Methods and Results: By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients, but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing human amylin in the pancreas ( HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at the sarcolemma induces oxidative stress and Ca 2+ dysregulation. In time, HIP rats developed cardiac hypertrophy and left‐ventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed reduced cardiac hypertrophy and left‐ventricular dilation. The cardioprotective mechanisms included the mitigation of amylin‐induced cardiac oxidative stress and Ca 2+ dysregulation. Conclusions: The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin‐mediated cardiotoxicity.